Business
-
SoftOx Solutions has announced a restructuring plan that includes shutting down its own GMP facility, laying off employees, and outsourcing further development of its SoftOx inhalation solution (SIS) to the University of Copenhagen. The company… Read more . . .
-
Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of “a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention… Read more . . .
-
Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in “a near term milestone payment” as well as $3 million… Read more . . .
-
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According… Read more . . .
-
Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the… Read more . . .
-
Destiny Pharma and SporeGen have announced that Vietnamese biotechnology company Huro Biotech has acquired non-exclusive manufacturing rights for SPOR-COV bacillus nasal spray as well as exclusive marketing rights to the nasal spray in Vietnam. Huro… Read more . . .
-
Amphastar Pharmaceuticals will pay Eli Lilly $500 million up front, an additional $125 million after one year, and up to $450 million in sales milestone payments for the rights to Baqsimi intranasal dry powder glucagon. The company… Read more . . .
-
Ritedose Corporation, which says that it is the largest manufacturer of albuterol sulfate inhalation solution in the US, announced that it has begun compounding 5 mg/ml albuterol sulfate inhalation solution ampules through the 503B manufacturing process in response… Read more . . .
-
Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL.… Read more . . .
-
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company’s AER-01 inhaled mucolytic for the treatment of COPD, the company… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland